X

Sign up for Equitymaster's free daily newsletter, The 5 Minute WrapUp and get access to our latest Multibagger guide (2018 Edition) on picking money-making stocks.

This is an entirely free service. No payments are to be made.


Download Now Subscribe to our free daily e-letter, The 5 Minute WrapUp and get this complimentary report.
We hate spam as much as you do. Check out our Privacy Policy and Terms Of Use.
Compare Orchid Chemicals with Lupin Ltd - Equitymaster
  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

ORCHID PHARMA LTD vs LUPIN LTD - Comparison Results

ORCHID PHARMA LTD    Change

Orchid Chemicals & Pharmaceuticals Ltd. (Orchid) is today a globally recognized, integrated pharmaceutical company with core competencies in the development and manufacture of Active Pharmaceutical Ingredients (APIs) and Finished Dosage Forms as well... More

LUPIN LTD 
   Change

Lupin is a leading pharmaceutical company with a strong presence in anti-infective, cardiovascular and asthma. Apart from having a strong domestic presence, the company markets its products in the regulated markets of the US and Europe and semi-regul... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    ORCHID PHARMA LTD LUPIN LTD ORCHID PHARMA LTD/
LUPIN LTD
 
P/E (TTM) x -0.5 19.9 - View Chart
P/BV x 0.4 2.7 13.7% View Chart
Dividend Yield % 0.0 0.9 -  

Financials

 ORCHID PHARMA LTD   LUPIN LTD
EQUITY SHARE DATA
    ORCHID PHARMA LTD
Sep-13
LUPIN LTD
Mar-17
ORCHID PHARMA LTD/
LUPIN LTD
5-Yr Chart
Click to enlarge
High Rs1941,750 11.1%   
Low Rs351,384 2.5%   
Sales per share (Unadj.) Rs276.5387.4 71.4%  
Earnings per share (Unadj.) Rs-79.256.6 -139.9%  
Cash flow per share (Unadj.) Rs-43.576.8 -56.6%  
Dividends per share (Unadj.) Rs07.50 0.0%  
Dividend yield (eoy) %00.5 0.0%  
Book value per share (Unadj.) Rs53.9298.9 18.0%  
Shares outstanding (eoy) m70.45451.58 15.6%   
Bonus/Rights/Conversions ESOPESOPS-  
Price / Sales ratio x0.44.0 10.2%   
Avg P/E ratio x-1.427.7 -5.2%  
P/CF ratio (eoy) x-2.620.4 -12.9%  
Price / Book Value ratio x2.15.2 40.5%  
Dividend payout %013.2 0.0%   
Avg Mkt Cap Rs m8,067707,513 1.1%   
No. of employees `0002.816.8 16.7%   
Total wages/salary Rs m2,52728,495 8.9%   
Avg. sales/employee Rs Th6,956.110,418.3 66.8%   
Avg. wages/employee Rs Th902.51,697.0 53.2%   
Avg. net profit/employee Rs Th-1,993.01,523.0 -130.9%   
INCOME DATA
Net Sales Rs m19,477174,943 11.1%  
Other income Rs m4071,065 38.2%   
Total revenues Rs m19,884176,008 11.3%   
Gross profit Rs m1,10344,931 2.5%  
Depreciation Rs m2,5199,122 27.6%   
Interest Rs m5,2271,525 342.7%   
Profit before tax Rs m-6,23635,349 -17.6%   
Minority Interest Rs m20-72 -27.5%   
Prior Period Items Rs m083 0.0%   
Extraordinary Inc (Exp) Rs m5110-   
Tax Rs m-1259,785 -1.3%   
Profit after tax Rs m-5,58025,575 -21.8%  
Gross profit margin %5.725.7 22.0%  
Effective tax rate %2.027.7 7.3%   
Net profit margin %-28.714.6 -196.0%  
BALANCE SHEET DATA
Current assets Rs m11,014119,542 9.2%   
Current liabilities Rs m32,06061,206 52.4%   
Net working cap to sales %-108.133.3 -324.0%  
Current ratio x0.32.0 17.6%  
Inventory Days Days9576 124.8%  
Debtors Days Days3490 37.3%  
Net fixed assets Rs m29,440131,660 22.4%   
Share capital Rs m705903 78.0%   
"Free" reserves Rs m2,043134,073 1.5%   
Net worth Rs m3,800134,976 2.8%   
Long term debt Rs m9,01856,478 16.0%   
Total assets Rs m46,510266,073 17.5%  
Interest coverage x-0.224.2 -0.8%   
Debt to equity ratio x2.40.4 567.2%  
Sales to assets ratio x0.40.7 63.7%   
Return on assets %-0.810.2 -7.5%  
Return on equity %-146.918.9 -775.1%  
Return on capital %-3.719.3 -19.4%  
Exports to sales %37.90-   
Imports to sales %22.60-   
Exports (fob) Rs m7,378NA-   
Imports (cif) Rs m4,406NA-   
Fx inflow Rs m7,51381,885 9.2%   
Fx outflow Rs m5,64921,506 26.3%   
Net fx Rs m1,86560,378 3.1%   
CASH FLOW
From Operations Rs m1,68241,148 4.1%  
From Investments Rs m-9,860-25,287 39.0%  
From Financial Activity Rs m6,6444,332 153.4%  
Net Cashflow Rs m-1,53520,193 -7.6%  

Share Holding

Indian Promoters % 32.3 46.6 69.3%  
Foreign collaborators % 0.0 0.2 -  
Indian inst/Mut Fund % 4.6 11.3 40.7%  
FIIs % 3.3 31.9 10.3%  
ADR/GDR % 4.6 0.0 -  
Free float % 55.3 10.1 547.5%  
Shareholders   84,811 98,259 86.3%  
Pledged promoter(s) holding % 54.9 0.0 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare ORCHID PHARMA LTD With:   PLETHICO PHARMA  BIOCON LTD  FULFORD INDIA  ALKEM LABORATORIES  AJANTA PHARMA  

Compare ORCHID PHARMA LTD With:   MYLAN (US)  ACTAVIS (US)  ADCOCK INGRAM (S. Africa)  TEVA PHARMA (Israel)  



Today's Market

Strong Finish to the Week; Metal & Pharma Stocks Gain(Closing)

Indian share markets finished the trading session on a strong note amid firm Asian markets after comments from a Federal Reserve official eased worries about faster rate hikes in US.

Related Views on News

Lupin: US market Declines Due to Higher Base Effect of FY17 (Quarterly Results Update - Detailed)

Feb 9, 2018

Price erosion in generic US drugs continues but seems to be bottoming out.

Lupin: US Markets Drags down Revenues and Net Profits (Quarterly Results Update - Detailed)

Nov 2, 2017

Domestic markets registers robust growth in the quarter

Lupin: Bigger Challenges or Bigger Margin of Safety? (Quarterly Results Update - Detailed)

Aug 14, 2017

GST impact coupled with price erosion in US leads to lower profits for the quarter.

Lupin: Decline in US Business Impacts Overall Growth (Quarterly Results Update - Detailed)

May 29, 2017

Currency fluctuation and one time provision impacts operating margins.

Aster DM Healthcare (IPO)

Feb 10, 2018

Should you subscribe to the IPO of Aster DM Healthcare Ltd?

More Views on News

Most Popular

The Foundation for Sensex 100,000 is Laid(The 5 Minute Wrapup)

Feb 17, 2018

Top three reasons for Tanushree's presentation at Equitymaster Conference to be centered around a possible 30% correction.

India's Rs 1,66,276 Crore Problem(Vivek Kaul's Diary)

Feb 15, 2018

That's the loss, the government owned public sector enterprises are expected to make this year.

The Big Gamble(The Honest Truth)

Feb 15, 2018

Once you accept the fact that elections are round the corner and that this budget is geared to reach a 40% target, everything makes sense.

How I Beat the Index by 2x... And Why I Believe This Could Happen Again(Smart Contrarian)

Feb 12, 2018

Will Microcap Millionaires be able to replicate its past performance of beating the index by 2x?

NPAs Set to Rise Further with New RBI Rules(Chart Of The Day)

Feb 15, 2018

The RBI overhauls bad loan framework. Banks may come under additional pressure due to rising NPAs and increased provisioning.

More

Small Investments
BIG Returns

Zero To Millions Guide 2018
Get our special report, Zero To Millions
(2018 Edition) Now!
We will never sell or rent your email id.
Please read our Terms

ORCHID PHARMA LTD SHARE PRICE


Feb 23, 2018 (Close)

TRACK ORCHID PHARMA LTD

  • Track your investment in ORCHID PHARMA LTD with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

MORE ON ORCHID PHARMA LTD

ORCHID PHARMA LTD 5-YR ANALYSIS

COMPARE ORCHID PHARMA LTD WITH

MARKET STATS